Abstract

How cell-to-cell copy number alterations that underpin genomic instability1 in human cancers drive genomic and phenotypic variation, and consequently the evolution of cancer2, remains understudied. Here, by applying scaled single-cell whole-genome sequencing3 to wild-type, TP53-deficient and TP53-deficient;BRCA1-deficient or TP53-deficient;BRCA2-deficient mammary epithelial cells (13,818 genomes), and to primary triple-negative breast cancer (TNBC) and high-grade serous ovarian cancer (HGSC) cells (22,057 genomes), we identify three distinct ‘foreground’ mutational patterns that are defined by cell-to-cell structural variation. Cell- and clone-specific high-level amplifications, parallel haplotype-specific copy number alterations and copy number segment length variation (serrate structural variations) had measurable phenotypic and evolutionary consequences. In TNBC and HGSC, clone-specific high-level amplifications in known oncogenes were highly prevalent in tumours bearing fold-back inversions, relative to tumours with homologous recombination deficiency, and were associated with increased clone-to-clone phenotypic variation. Parallel haplotype-specific alterations were also commonly observed, leading to phylogenetic evolutionary diversity and clone-specific mono-allelic expression. Serrate variants were increased in tumours with fold-back inversions and were highly correlated with increased genomic diversity of cellular populations. Together, our findings show that cell-to-cell structural variation contributes to the origins of phenotypic and evolutionary diversity in TNBC and HGSC, and provide insight into the genomic and mutational states of individual cancer cells.

Original languageEnglish
Pages (from-to)106-115
Number of pages10
JournalNature
Volume612
Issue number7938
DOIs
StatePublished - 1 Dec 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2022, The Author(s).

Funding

This project was supported by the BC Cancer Foundation at BC Cancer and Cycle for Survival supporting the Memorial Sloan Kettering Cancer Center. S.P.S. holds the Nicholls Biondi Chair in Computational Oncology and is a Susan G. Komen Scholar (GC233085). S.A. holds the Nan and Lorraine Robertson Chair in Breast Cancer and is a Canada Research Chair in Molecular Oncology (950–230610). Additional funding was provided by a Terry Fox Research Institute grant (1082), a Canadian Cancer Society Research Institute Impact program grant (705617), a CIHR grant (FDN-148429), Breast Cancer Research Foundation awards (BCRF-18-180, BCRF-19-180 and BCRF-20-180), a MSK Cancer Center Support Grant/Core Grant (P30 CA008748), National Institutes of Health grants (1RM1 HG011014-01 and P50 CA247749-01), a CCSRI grant (705636), the Cancer Research UK Grand Challenge Program and the Canada Foundation for Innovation (40044) to S.A. and S.P.S. M.J.W. is supported by a National Cancer Institute Pathway to Independence award (K99CA256508). This project was supported by the BC Cancer Foundation at BC Cancer and Cycle for Survival supporting the Memorial Sloan Kettering Cancer Center. S.P.S. holds the Nicholls Biondi Chair in Computational Oncology and is a Susan G. Komen Scholar (GC233085). S.A. holds the Nan and Lorraine Robertson Chair in Breast Cancer and is a Canada Research Chair in Molecular Oncology (950–230610). Additional funding was provided by a Terry Fox Research Institute grant (1082), a Canadian Cancer Society Research Institute Impact program grant (705617), a CIHR grant (FDN-148429), Breast Cancer Research Foundation awards (BCRF-18-180, BCRF-19-180 and BCRF-20-180), a MSK Cancer Center Support Grant/Core Grant (P30 CA008748), National Institutes of Health grants (1RM1 HG011014-01 and P50 CA247749-01), a CCSRI grant (705636), the Cancer Research UK Grand Challenge Program and the Canada Foundation for Innovation (40044) to S.A. and S.P.S. M.J.W. is supported by a National Cancer Institute Pathway to Independence award (K99CA256508).

FundersFunder number
National Cancer Institute PathwayK99CA256508
Susan G. Komen Scholar950–230610, GC233085
National Institutes of HealthP50 CA247749-01, 705636
National Human Genome Research InstituteRM1HG011014
Breast Cancer Research FoundationBCRF-20-180, P30 CA008748, BCRF-19-180, BCRF-18-180
Canadian Cancer Society Research Institute705617
Canadian Institutes of Health ResearchFDN-148429
Canada Foundation for Innovation40044
Cancer Research UK
Terry Fox Research Institute1082

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Single-cell genomic variation induced by mutational processes in cancer'. Together they form a unique fingerprint.

    Cite this